This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
Age 25-80 years.
Confirmed diagnosis of bronchiectasis.
FEV1 ≥35% predicted; DLCO ≥30% and <80% predicted.
Pregnancy, lactation, or plans for pregnancy within 1 year.
Active malignancy or history of malignancy.
Positive serology for HIV, HBV, HCV, or syphilis.